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Purpose of review: “Omics” technologies, developed for the massive analysis of the 
major biologically relevant molecules (genes, proteins, metabolites) have been applied to 
the study of osteoarthritis (OA) for more than a decade.  
Recent findings: “Omics” studies have undoubtedly contributed to increase the 
knowledge on pathogenic processes related with OA, and have provided hundreds to 
thousands of molecules that might have a putative biomarker utility for this disease. 
Summary: This review describes the most recent “omics” studies in OA research, their 
conclusions, and discuss those remaining challenges. Still many validation studies must 
be performed in large and well characterized cohorts for the translation of the findings 
from “omics” strategies to clinical applications. The development of tools for the 
intelligent integration of “omics” data with clinical and imaging information is also 
mandatory to take full profit of the work that has been already performed. 
 





































































The “omics” technologies were developed for the large-scale analysis of the major 
biologically relevant molecules: DNA, RNA, proteins and metabolites (amino acids, 
lipids, etc.). Over the last decade, these technologies have been extensively applied for 
the study of osteoarthritis (OA) pathogenesis and for the discovery of novel molecules 
with marker usefulness for this disease. This review will describe the most recent 
“omics” studies in OA research and their conclusions, and discuss those remaining 
challenges.    
 
Recent achievements in genomics studies 
In genomics, recent technological advances expanded the amount of “omic” data to 
higher levels, including genome sequencing, epigenetics, and transcriptomics. The aims 
of each of these molecular approaches are the understanding of the mechanisms 
underlying OA, and the identification of molecular markers to predict disease onset and 
progression (Table 1).  
During the last decade, genome-wide association studies (GWAS) have been the 
preferred tool to study the genetics of late onset knee, hip and hand OA (1-3). Results 
derived from these studies reported that, as for many complex diseases, there is no single 
genetic variant responsible for OA. However, up to thousands of loci could be potentially 
associated, each with a small effect (4). To date, this method of analysis identified 19 
independent susceptibility loci for OA (4). Some of them, such as rs1180992 at DOT1L 
gene, rs2862851 at TGFA, rs10471753 at PIK3R1, rs2236995 at SLBP, rs496547 at 
TREH and rs10948172 at RUNX2, are also significantly associated with a decreased 
cartilage thickness in terms of clinical radiographic endophenotyping according to mJSW 


































































in GWAS, enabling the detection of genes with potential functional importance that were 
not revealed in previous case-controls studies due to disease heterogeneity. This is the 
case of a recent meta-analysis of clinically relevant endophenotypes in hip OA, where the 
authors reported suggestive evidence for association of 6 variants located in novel genes 
such as LRCH1 or STT3B with increased joint space narrowing and the bone remodeling 
response (6). A very recent study performed a GWAS of total hip replacements based on 
variants identified through whole-genome sequencing, concluding that two variants: a 
missense mutation in the COMP gene and a frameshift variant in the CHADL gene, were 
significantly associated with an increased risk of hip replacement (7). 
Mitochondrial genetics has also been consolidated as a contributor to the risk of knee OA. 
Two recent meta-analyses showed a significant association of specific mtDNA variants 
with the rate of incidence and progression of OA in well-defined prospective cohorts such 
as the Cohort Hip and Cohort Knee (CHECK) and the Osteoarthritis Initiative (OAI).  In 
these studies, haplogroup J and superhaplogroup JT associate with a decreased rate of 
incident knee OA at 8 years and a decreased rate of radiographic progression, 
respectively (8, 9). 
DNA methylation in OA has also been the focus of many studies during the last years. 
The first studies relied on the analysis of specific CpG sites in promoter regions of 
candidate genes involved in the OA process such as the matrix metalloproteinases (10). 
However, the last works were based on genome-wide DNA methylation analyses in 
articular cartilage (11, 12). In the last year, a very interesting study analyzed DNA 
methylation changes in three regions of the subchondral bone of the tibial plateau to 
represent early, intermediate and late stages of OA, and compare them with those on the 
site-matched cartilage. Authors concluded that methylation changes in the subchondral 


































































number of differentially reported sites. However, enrichment analyses of all of them 
indicate similar pathways, including embryonic morphogenesis, inflammation and 
skeletal development (14). Finally, according to OA methylation changes, Vidal-Bralo 
and colleagues concluded that premature epigenetic aging is a characteristic of OA 
cartilage, being a component of the disease pathogenesis that reflects damage and 
vulnerability (15). 
Several studies have used arrays to investigate gene expression changes in OA, mainly in 
articular cartilage (16). However, over the last years, these transcriptomic assays were 
performed primarily to validate methylation analyses (11, 17) and actually are being 
substituted by the most sensitive RNA-seq assay. Considering the proposed hypothesis 
that the regenerative potential of human mesenchymal stem cells (hMSCs) is altered in 
advanced-stage OA, some studies analyzed the methylation and/or expression profile of 
these cells. One of these works performed a large-scale gene expression profile of bone 
marrow stromal cells (BMSCs) from osteoarthritic cells compared with healthy, using a 
microarray from Affymetrix. This study revealed up to 690 intergroup differentially 
regulated genes between BMSCs from OA donors and healthy controls (18). Another 
relevant work described a validation transcriptomic analysis by RNA-seq to compare the 
expression patterns of hMSCs from patients with fractures and OA. In this study, the 
authors denote two areas of potential interest for discovering new therapeutic targets for 
bone mass disorders and bone regeneration: those related to the mechanisms stimulating 
MSCs proliferation and those impairing their terminal differentiation (17). Finally, the 
availability of data from the Gene Expression Omnibus (GEO) database permitted the 
bioinformatic analyses and meta-analyses of gene expression profiles. This is the case of 
one study of disease-related genes of synovial membrane associated with progression of 


































































response and 196 down-regulated genes related with cell cycle processes (19). Another 
work identified a small overlap between the differentially expressed genes of the cartilage 
compared to those of the synovium. The authors suggest the existence of different 
pathogenic mechanisms that are specific of the synovium, since a much higher amount of 
differentially expressed genes were found in this tissue when comparing OA samples 
with healthy controls (20). 
Finally, a relevant number of studies were performed most recently to discover 
differentially expressed micro-ribonucleic acids (miRNAs) in cartilage or bone between 
OA and controls. However, there is almost no overlap between those reported to be 
differentially expressed with statistical significance (14). Analyses of circulating 
miRNAs in serum or synovial fluid, which may reflect altered tissue expression in OA 
and have thus a potential use as disease biomarkers, are of special interest. The first study 
on this area was conducted by Beyer and colleagues in a large prospective cohort 
consisting of 816 Caucasian individuals, and explored the association between serum 
levels of miRNAs and the development of severe OA. The authors identified the miRNA 
let-7e as a potential predictor for severe knee or hip OA (21). A more recent study aimed 
to identify miRNAs in synovial fluid useful to differentiate between early- and late-stage 
knee OA, and led to the identification of a panel of seven circulating miRNAs (22). 
 
Characterization of OA related-proteins and identification of putative 
biomarkers by proteomics 
After more than a decade of proteomics studies performed in OA, these approaches have 
contributed to a better understanding of disease pathogenesis and the identification of 
novel protein markers. The most recent descriptive studies in this field have been focused 


































































that occur in this tissue. This has been achieved by qualitative and quantitative shotgun 
analyses of the different layers and types (knee or hip) of OA and healthy tissues (23), 
and also by the evaluation of the response to IL-1α in cartilage using an in vitro model of 
mouse tissue explants (24). The analysis of chondrocyte secretomes has been reported as 
a valuable strategy to explore the processes related with ECM remodeling and the 
molecular mechanisms driven by the cell in response to different stimuli (25). 
Accordingly, a recent proteomic study on secretomes reports the effects of nicotine on 
both OA and healthy chondrocytes treated with IL-1β, and suggests a negative effect of 
this drug on the joint (26). Apart from these shotgun studies, the progression of matrix 
degradation in response to mechanical damage and cytokine treatment of human knee 
cartilage explants has been also evaluated using targeted proteomics (27). Different 
protein domains of aggrecan, COMP neoepitopes and collagen pro-peptides were 
measured throughout a 21-day culture period, being some of them potentially relevant as 
biomarkers for post-traumatic OA.  
Biological fluids such as synovial fluid, plasma and serum, have been also extensively 
studied for the search of protein markers for OA (Table 2). In a discovery step, 
suspension beads-based protein arrays were used to screen serum samples from a cohort 
including OA and RA patients, and healthy controls. After linear regression analysis 
adjusting for sex, age and body mass index (BMI) three proteins were significantly 
elevated in serum from OA patients compared to controls: C3, ITIH1 and S100A6. A 
panel consisting of these three proteins had an area under the curve of 0.82 for the 
classification of OA and control samples (28). In an analogous study, a panel of 7 
proteins was found quantitatively different in sera from OA, RA and healthy controls 
(29). A targeted proteomic analysis was also performed on sera from OA patients and 


































































for the multiplexed monitoring of 14 biomarker candidates for OA, and verified the 
increased amount of Haptoglobin and von Willebrand Factor in OA patients.  
Finally, protein modifications have also been recently explored using proteomic 
approaches. In one of this works, glycated, oxidized and nitrated proteins and amino 
acids were detected in synovial fluid and plasma of arthritic patients. Their combination 
with hydroxyproline and anti-CCP antibody status provided a plasma-based biochemical 
test of 0.92 sensitivity and 0.90 specificity for early-stage OA (31). Using a very different 
strategy, N-glycosylation of proteins was analyzed by mass spectrometry imaging (MSI) 
in subchondral bone from knee OA patients (32). The latter study demonstrates the 
usefulness of this novel technology to complement the proteomic data with valuable 
spatial information (33). 
 
Metabolomic approaches to profile OA-related processes and identify 
novel biomarkers  
Being the youngest of the “omics” technologies, methods for the study of the 
metabolome have greatly evolved in the last years, also in the field of OA.  
Two metabolomic approaches were recently carried out to gain insight into pathogenic 
processes characteristic of OA, such as subchondral bone sclerosis or osteophyte 
formation. In the first study, a metabolic profiling was carried out on subchondral bone 
from patients with primary OA (34). 68 metabolites were identified to be significantly 
changed in the sclerotic tissue compared with the non-sclerotic. Metabolites such as 
taurine, hypotaurine, beta-alanine, L-carnitine, and glycerophospholipids were found to 
be related with this pathological process. In the work on osteophyte formation (35), 
authors found metabolic variations between extracts of osteophyte cartilage tissues and 


































































destruction of boundary layers, and self-restoration. Phenylalanine metabolism was also 
highly correlated with osteophyte formation.  
Regarding the identification of metabolites with putative biomarker usefulness for the 
disease, metabolomic analyses have been performed recently in synovial fluid, plasma 
and urine from OA patients. The conclusions from these studies are summarized in Table 
3. In synovial fluid, twenty-eight metabolites (including malate, ethanolamine, squalene, 
glycerol, myristic acid, oleic acid, lanosterol, heptadecanoic acid, and capric acid) were 
identified as critical metabolites for discriminating between early and late OA. These 
were robustly altered along the radiographic stage of knee OA (36). In a similar study, six 
different metabolites (glutamine, 1,5-anhydroglucitol, gluconic lactone, tyramine, 
threonine, and 8-aminocaprylic acid) were strongly associated with knee OA. Gluconic 
lactone concentration was also significantly different between OA and RA (37). Finally, a 
recent lipidomic analysis has been carried out, describing the identification of thirty-
seven lipids in the soluble fraction of SF from OA and RA patients. Among them are 
polyunsaturated fatty acids and their pro-inflammatory and pro-resolving lipoxygenase 
(LOX) and cyclooxygenase (COX) pathway markers. This work shows for the first time 
that resolution pathways are present in SF from OA patients (38).  
In plasma, Zhang and colleagues reported the identification of lower arginine 
concentrations in patients with knee OA compared to controls (39). They hypothesize this 
is due to an over activity of arginine to ornithine pathway, which leads to an imbalance 
between cartilage repair and degradation. In another study from the same group, the 
branched chain amino acids to histidine ratio was confirmed to be associated with 
advanced knee OA, and also the lysophosphatidylcholines (lysoPCs) to 


































































more likely to undergo total knee replacement than those with the ratio <0.09 during a 
10-year follow-up (40).  
Finally, a very interesting study described metabolomic profiles in urine, distinguishing 
OA progressors (≥0.7 mm decrease in JSW at 18 months) from non-progressors (≤0.35 
mm decrease in JSW). Glycolate, hippurate, and trigonelline were among the important 
metabolites for discriminating these groups at baseline, whereas alanine, N,N-
dimethylglycine, glycolate, hippurate, histidine, and trigonelline, were among the 
metabolites that were important at 18 months. These findings support a role for metabolic 
factors in the progression of knee OA, and suggest that measurement of metabolites could 
be useful to predict progression (41). Altogether, metabolomic studies have reported a 
number of molecules that play a role in the pathogenic process of OA and may be useful 
markers for disease progression studies.  
 
Remaining challenges 
Given the great amount of information that the “omics” approaches has provided to the 
investigation in OA, still there is a bottleneck in translating these findings to useful tools 
in clinical routines. Validation studies, capable to monitorize panels of biomarker 
candidates and qualify them for a clinical application, are still minority. In genomics, 
several meta-analyses have been performed for the systematic evaluation of the findings 
obtained in GWAS, and some validation studies have led to the definition of 
polymorphisms associated with OA susceptibility, severity and rate of progression. Such 
type of analyses is yet almost absent in the field of proteomics and metabolomics, due to 
the higher complexity of the multiplexed analysis of metabolites and (even more) 
proteins. In this field, the ultimate advances in targeted proteomics and metabolomics 


































































platforms) are expected to facilitate their application in larger cohorts and under the 
frame of clinical trials.  
To date, clinical data has been combined with the evaluation of genetic polymorphisms to 
predict primary knee OA progression (42), and also with imaging markers to generate 
prediction algorithms of structural progression (43). Furthermore, a recent study 
evaluated the predictive validity of 18 protein biomarkers in serum and urine samples 
from the OAI cohort (44). Considering the promising results obtained in these 
independent works, the next objective would be to develop combined tools 
(genes+proteins+metabolites+imaging) to identify patients with high risk of progression 
who will respond to a specific treatment. The integration of “omics” information with 
clinical and imaging data is a highly promising strategy for the identification of 
phenotype profiles. The APPROACH project (Applied Public-Private Research enabling 
OsteoArthritis Clinical Headway), currently ongoing, contributes to this integration by 
combining biomedical information (clinical, genomic, proteomic, metabolomic, x-ray and 
MRI) from knee OA patients and controls into a unified bioinformatics platform (45).  
 
Conclusion 
“Omics” technologies applied in the last decade for the study of OA have provided 
thousands of molecules related with this disease. Further validation of these findings will 
allow moving from single to multiplex biomarkers, defining the so-called molecular 
signatures related with a specific OA phenotype, or either those that could contribute to 
an increased diagnostic accuracy, disease progression studies, or to predict the response 
of each patient to a treatment. Leveraging multiomics technology to combine this 
information with the clinical data may much better define these biomarker profiles and 




































































 The high complex nature of osteoarthritis has hindered the development of tools 
for the precise evaluation and therapeutic management of this disease. 
 
 “Omics” technologies have contributed to increase the knowledge on OA 
pathogenesis, and have provided lists of molecules related with this disease. 
 
 Further validation studies are still needed to translate the findings from “omics” 
studies to clinical applications. 
 
 A tool able to combine the molecular information generated by the “omics” 
studies with imaging and clinical data would be highly valuable to facilitate 
precision medicine strategies in OA.  
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Table 1. Genomics studies in OA disease from 2016  
Study Type of study Trait/Phenotype Findings 
Warner, 2017 Review GWAS OA susceptibility Description of the most robust SNPs associated 
with OA with genome-wide significance 
Castaño-Betancourt, 2016 GWAS mJSW 6 variants associated with decreased cartilage 
thickness 
Panotsopoulou, 2017 Meta-analysis JSN and bone 
remodeling 
6 variants associated with increased JSN and 
bone remodeling response 
Styrkarsdottir, 2017 WGS/GWAS Hip replacement 2 variants associated with increased risk of hip 
replacement 
Fernández-Moreno, 2017a Genetic association Incident knee OA mtDNA haplogroup J associated with a 
decreased rate of incident knee OA 
Fernández-Moreno, 2017b Genetic association Rx knee OA 
progression 
mtDNA cluster JT associated with a decreased 
risk of Rx knee OA progression 
Zhang, 2016 Genome-wide 
methylation in bone 
and cartilage 
Stages of OA Changes in subchondral bone precede the 
methylation changes in cartilage 
Vidal-Bralo, 2016 DNA methylation Epigenetic aging in 
cartilage 
Premature epigenetic aging as a characteristic 
of OA cartilage 
Stiehler, 2016 Gene expression 
array in BMSCs 
Regenerative 
potential of BMSCs 
in advanced OA 
690 intergroup differentially regulated genes 
between OA and healthy controls 
Del Real, 2017 RNA-seq in hMSCs Differential 
expression patterns 
between OP and OA 
Mechanisms stimulating hMSCs proliferation 
and mechanisms impairing their terminal 
differentiation as areas of potential interest for 
new therapeutic targets 
Dong, 2016 Bioinformatic analysis 
of gene expression 
patterns of SM 
OA progression 401 up-regulated genes involved in inflammatory 
response and 196 down-regulated genes 
involved in cell cycle 
Park, 2016 Gene expression 
between cartilage 
and synovium 
OA susceptibility There are different pathogenic mechanisms that 
are specific for the synovium in OA 
Beyer, 2015 Circulant miRNAs in 
serum 
OA severity miRNA let-7e as a potential predictor for severe 
knee or hip OA 
Li, 2016 Circulant miRNAs in 
SF 
Stages of OA 7 circulating miRNAs differentially expressed 
between late-stage OA and early-stage OA 
OA: osteoarthritis; GWAS: genome-wide association studies; SNP: single nucleotide polymorphism; mJSW: minimum joint space 
width; JSN: joint space narrow; mtDNA: mitochondrial DNA; WGS: whole-genome sequencing; BMSCs: bone marrow stromal 
cells; hMSCs: human mesenchimal stem cells; OP: osteoporosis; SM: synovial membrane; SF: synovial fluid; miRNA: micro RNA 
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Table 2. Circulating proteins with putative biomarker utility for OA found in the most recent proteomic studies. 
Protein Biomarker utility Reference 
C3, ITIH1, S100A6 Knee OA diagnosis Lourido, 2017 
PLTP, NRAM1/SLC11A1 Knee OA diagnosis Sierra-Sánchez, 2017 
HPT, VWF OA diagnosis Fernández-Puente, 2017 
Glycated, oxidized and nitrated proteins and amino acids Early OA diagnosis Ahmed, 2016 
C3: Complement C3, HPT: Haptoglobin; ITIH1: Inter-alpha trypsin inhibitor heavy chain H1; OA: osteoarthritis; 
PLTP: phospholipid transfer protein; NRAM1/SLC11A1: Natural resistance-associated macrophage protein 1; 




Table 3. Metabolites with putative biomarker usefulness in OA, described in the most recent metabolomic studies. 
Metabolite Type of 
sample 
Biomarker utility Reference 
Malate, ethanolamine, squalene, glycerol, myristic 






Glutamine, 1,5-anhidroglucitol, gluconic lactone, 
tyramine, threonine and 8-aminocaprilyc acid 
Synovial fluid Knee OA diagnosis Zheng, 2017 
Polyunsaturated fatty acids, LOX and COX pathway 
markers 
Synovial fluid Diagnosis Jonsadottir, 2017 
Arginine (low concentrations) Plasma Knee OA diagnosis Zhang, O&C 2016 





Glycolate, hippurate, trigonelline Urine Progression predictors Loeser, 2016 
Alanine, N,N-dimethylglycine, glycolate, hippurate, 
histidine, trigonelline 
Urine Progression markers Loeser, 2016 
COX: ciclooxygenase; LOX: lipoxygenase; lysoPCs: lysophosphatidylcholines; PCs: Phosphaticylcholines; OA: osteoarthritis.  
 
